🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. A Study to Learn How Different Amounts of the Study Medicine Called PF-07293893 are Tolerated and Act in the Body of Healthy Adults.

    Pfizer Australia Pty Ltd

    heart failure with preserved ejection fraction

    phase 1 other active

    1 trial

  2. A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 are Tolerated and Act in the Body in Healthy Adults

    Pfizer Australia Pty Ltd

    Heart failure

    phase 1 other active

    1 trial

  3. A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 are Tolerated and Act in the Body in Healthy Adults

    Pfizer Australia Pty Ltd

    Clonal hematopoiesis

    phase 1 other active

    1 trial

  4. A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 are Tolerated and Act in the Body in Healthy Adults.

    Pfizer Australia Pty Ltd

    clonal hematopoiesis

    phase 1 other active

    1 trial

  5. A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 are Tolerated and Act in the Body in Healthy Adults

    Pfizer Australia Pty Ltd

    IgA nephropathy

    phase 1 other active

    1 trial

  6. A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 are Tolerated and Act in the Body in Healthy Adults

    Pfizer Australia Pty Ltd

    CCI

    phase 1 other active

    1 trial

  7. A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults

    Pfizer Australia Pty Ltd

    Rheumatoid arthritis and Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  8. A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  9. A Study to Learn how Various Tablets of the Study Medicine Called Vepdegestrant are Taken up into the Blood in Healthy Adults

    Pfizer Australia Pty Ltd

    ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  10. A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  11. A Study to find out the safety, tolerability and interaction of drug with body (including the effect of Itraconazole on RO7268489) and also what the body does to RO7268489 after oral intake by healthy participants

    Hoffmann-La Roche

    Not applicable

    phase 1 other active

    1 trial

  12. A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS

    Alfasigma S.p.A.

    chronic intestinal pseudo-obstruction (CIPO)

    phase 1 other active

    1 trial

  13. A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

    Zealand Pharma A/S

    Weight management

    phase 1 other active

    1 trial

  14. A clinical research study investigating how the body processes the new compound petrelintide in people with kidney problems

    Zealand Pharma A/S

    Weight management

    phase 1 other active

    1 trial

  15. A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

    Pierre Fabre Medicament

    Participants with BRAF and/or NRAS mutation positive tumors

    phase 1 other active

    1 trial

  16. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  17. A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

    BioNTech SE

    HIV-1 infection

    phase 1 other active

    1 trial

  18. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  19. A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

  20. A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis

    Philogen S.p.A.

    Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

    phase 1 other active

    1 trial

  21. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  22. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  23. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

  24. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources